hepatocellular carcinoma
Conditions
Interventions
experimental group:TACE-HAIC combined with lenvatinib and tirelizumab for unresectable HCC
Sponsors
The Second People's Hospital of Yibin
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. HCC patients with BCLC B or C stage and unresectable after surgical evaluation; 2. Age 18-75 years old; 3. At least one measurable intrahepatic lesion; 4. Have not received local and systemic treatment for liver cancer in the past; 5. Liver function Child-Pugh grade A or B (CP-7B) and ECOG score = 3.0 × 10^9/L or absolute neutrophil count > 1.5 × 10^9/L, hemoglobin >= 8 g/dL, platelet count > 60 × 10^9/L; 7. Renal function: serum creatinine level 45%; 10. Patients who are not allergic to contrast media; patients who are informed and agree to participate in this study, have good clinical compliance, and are expected to survive for more than 3 months.
Exclusion criteria
Exclusion criteria: 1. Patients with other malignant tumors in the past; 2. Combined with organic diseases of important organs such as heart and kidney; 3. Previously received systemic treatment for liver cancer; 4. Hepatic decompensation (Child-Pugh C grade of liver function); 5. Patients with severe infectious diseases (> grade 2 infection; requiring antibiotic or surgical intervention or life-threatening infection); 6. Patients with diffuse liver cancer lesions and history of upper gastrointestinal bleeding or ascites; 7. Pregnancy or breastfeeding; 8. Severe allergy to contrast medium or other drugs; 9. Incomplete clinical data; lost to follow-up, patients with poor clinical compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate;disease control rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival;Tumor downstaging rate;Surgical conversion rate;Adverse events; | — |
Countries
China
Contacts
Public ContactJun Zhu
The Second People's Hospital of Yibin
Outcome results
None listed